Insulet (PODD) - 2025 Q2 - Quarterly Results

• Revenue of $649.1 million, up 32.9%, or 31.3% in constant currency, exceeds the high end of the Company's guidance range of 26.0% in constant currency ◦ Total Omnipod revenue of$ 639.0 million, up 33.0%, or 31.4% in constant currency ▪ U.S. Omnipod revenue of $453.2 million, up 28.7% ▪ International Omnipod revenue of$ 185.8 million, up 45.0%, or 38.8% in constant currency ◦ Drug Delivery revenue of $10.2 million • Gross margin of 69.7%, up 190 basis points over prior year • Operating income of$ 121.1 mil ...